Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin

Traditional antibiotic dosage adjustments target predetermined serum concentrations, whereas a host of in vitro studies and recent clinical trials establish that bacteria vary in their susceptibility. Dual individualization, which considers the variance in both antibiotic pharmacokinetics and bacterial susceptibility, has been employed to describe different rates of bacterial eradication in relation to varying serum concentrations. In patients with nosocomial pneumonia, one of the model compounds studied was cefmenoxime, where a target six-hour area under the serum concentration-time curve (AUC) of 140 micrograms.h/mL above minimum inhibitory concentration (MIC) was previously associated with bacterial eradication in an average of four days. The target AUC value of 140 micrograms.h/mL above MIC is unique to cefmenoxime. Ideally, there should be a dual individualized target useful to adjust the dose of any antibiotic. Computer simulations performed to evaluate this hypothesis suggested that each antibiotic had a unique value for target AUC above MIC. These simulations indicated that an optimal AUC above MIC was about 80 percent of the total AUC above the MIC. Predictable rates of bacterial eradication would presumably result from maintaining these relationships across the range of bacterial susceptibility and the range of serum concentration profiles. Each antibiotic has a unique and different 24-hour AUC over MIC value associated with bacterial eradication in 4 days. For cefmenoxime, the target was 540 area units over MIC per 24 hours, tobramycin with 34 area units, and ciprofloxacin with 23 area units per 24 hours.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. M. LeBlanc, J. F. Dasta, M. C. Pruchnicki, and J. J. Schentag Impact of disease States on the pharmacokinetics and pharmacodynamics of Angiotensin-converting enzyme inhibitors. J. Clin. Pharmacol., September 1, 2006; 46(9): 968 - 980. [Abstract] [Full Text] [PDF]

				J. W. Mouton, M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update J. Antimicrob. Chemother., May 1, 2005; 55(5): 601 - 607. [Abstract] [Full Text] [PDF]

				J. J. Campion, P. J. McNamara, and M. E. Evans Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4733 - 4744. [Abstract] [Full Text] [PDF]

				M. A. Zeitlinger, P. Dehghanyar, B. X. Mayer, B. S. Schenk, U. Neckel, G. Heinz, A. Georgopoulos, M. Muller, and C. Joukhadar Relevance of Soft-Tissue Penetration by Levofloxacin for Target Site Bacterial Killing in Patients with Sepsis Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3548 - 3553. [Abstract] [Full Text] [PDF]

				C. Joukhadar, H. Stass, U. Muller-Zellenberg, E. Lackner, F. Kovar, E. Minar, and M. Muller Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3099 - 3103. [Abstract] [Full Text] [PDF]

				M. L. Peterson, L. B. Hovde, D. H. Wright, G. H. Brown, A. D. Hoang, and J. C. Rotschafer Pharmacodynamics of Trovafloxacin and Levofloxacin against Bacteroides fragilis in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., January 1, 2002; 46(1): 203 - 210. [Abstract] [Full Text] [PDF]

				M. M. Sanchez-Recio, C.-I. Colino, and A. Sanchez-Navarro A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin J. Antimicrob. Chemother., March 1, 2000; 45(3): 321 - 328. [Abstract] [Full Text] [PDF]

				L. C. Strenkoski-Nix, A. Forrest, J. J. Schentag, and D. E. Nix Pharmacodynamic Interactions of Ciprofloxacin, Piperacillin, and Piperacillin/Tazobactam in Healthy Volunteers J. Clin. Pharmacol., November 1, 1998; 38(11): 1063 - 1071. [Abstract] [PDF]

				H. Peltola, P. Ukkonen, and H. Saxen Single-dose and Steady-state Pharmacokinetics of a New Oral Suspension of Ciprofloxacin in Children Pediatrics, April 1, 1998; 101(4): 658 - 662. [Abstract] [Full Text] [PDF]

				J. J. Schentag Antibiotic Dosing--Does One Size Fit All? JAMA, January 14, 1998; 279(2): 159 - 160. [Full Text] [PDF]